DS
STSA

David Shaw’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

David Shaw’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,232
Closed -$52K – 5827
2021
Q3 		$52K Sell
11,232
-3,396
-23% -$18K ﹤0.01% 4819
2021
Q2 		$103K Buy
+14,628
New +$78.9K ﹤0.01% 4549

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

David Shaw's STSA Position: Q4 2021 in Review

David Shaw sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2021, closing a stake of 11,232 shares — an estimated $52K sold.

David Shaw first reported a position in STSA in Q2 2021 and held it in 2 quarters. The position peaked at $103K in Q2 2021. 35 funds tracked by Wall St. Rank hold STSA as of Q4 2021.

  • David Shaw reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • David Shaw sold 11,232 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $52K.
  • David Shaw first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • David Shaw's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $103K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.